NovoCure (NVCR) Set to Announce Quarterly Earnings on Wednesday

NovoCure (NASDAQ:NVCR - Get Free Report) is scheduled to release its earnings data before the market opens on Wednesday, October 30th. Analysts expect NovoCure to post earnings of ($0.34) per share for the quarter. Persons interested in participating in the company's earnings conference call can do so using this link.

NovoCure (NASDAQ:NVCR - Get Free Report) last issued its earnings results on Thursday, July 25th. The medical equipment provider reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.09. The company had revenue of $150.40 million for the quarter, compared to analysts' expectations of $135.83 million. NovoCure had a negative net margin of 30.67% and a negative return on equity of 45.68%. The firm's quarterly revenue was up 19.3% on a year-over-year basis. During the same period in the prior year, the business earned ($0.54) EPS. On average, analysts expect NovoCure to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NovoCure Stock Up 0.2 %

NVCR stock traded up $0.03 during trading on Wednesday, reaching $16.18. 810,899 shares of the company traded hands, compared to its average volume of 1,321,439. The business has a 50 day simple moving average of $16.95 and a 200 day simple moving average of $17.79. NovoCure has a 12 month low of $10.87 and a 12 month high of $24.74. The company has a debt-to-equity ratio of 1.81, a quick ratio of 6.22 and a current ratio of 6.46. The company has a market capitalization of $1.75 billion, a price-to-earnings ratio of -10.24 and a beta of 0.70.

Analyst Ratings Changes

NVCR has been the topic of a number of research analyst reports. Wedbush restated an "outperform" rating and set a $24.00 price target on shares of NovoCure in a research note on Thursday, July 25th. Evercore ISI decreased their price target on shares of NovoCure from $21.00 to $18.00 and set an "in-line" rating for the company in a report on Tuesday, October 1st. Wells Fargo & Company dropped their price objective on shares of NovoCure from $42.00 to $40.00 and set an "overweight" rating on the stock in a report on Friday, July 26th. Finally, HC Wainwright upgraded NovoCure from a "neutral" rating to a "buy" rating and raised their target price for the stock from $24.00 to $30.00 in a research note on Wednesday, October 16th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, NovoCure presently has an average rating of "Moderate Buy" and a consensus price target of $26.17.

NovoCure Company Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua.